White Pine Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

White Pine Capital’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-8,180	Closed	-$645K	–	225
2017 Q2	$645K	Buy	8,180 +2,475	+43%	+$202K	0.25%	117
2017 Q1	$473K	Buy	5,705 +30	+0.5%	+$2.23K	0.19%	145
2016 Q4	$450K	Hold	5,675	–	–	0.19%	136
2016 Q3	$397K	Buy	5,675 +300	+6%	+$16.6K	0.17%	155
2016 Q2	$208K	Buy	+5,375	New	+$224K	0.09%	193

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

White Pine Capital's EGRX Position: Q3 2017 in Review

White Pine Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2017, closing a stake of 8,180 shares — an estimated $645K sold.

White Pine Capital first reported a position in EGRX in Q2 2016 and held it in 5 quarters. The position peaked at $645K in Q2 2017. 169 funds tracked by Wall St. Rank hold EGRX as of Q3 2017.

White Pine Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
White Pine Capital sold 8,180 Eagle Pharmaceuticals, Inc. shares in Q3 2017, an estimated $645K.
White Pine Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 5 quarters.
White Pine Capital's Eagle Pharmaceuticals, Inc. position peaked at $645K in Q2 2017.
169 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2017.

Based on White Pine Capital's 13F filing for Q3 2017, filed 13 Nov 2017.